Gilead, Merck’s phase 3 data back first weekly HIV pill

Detailed phase 3 results from two Islend clinical trials confirmed that a once-weekly, single-tablet combination of Merck’s islatravir and Gilead’s lenacapavir matches daily treatments like Biktarvy at maintaining HIV viral suppression

Source: FiercePharma